Demographic, procedural and 30-day safety results from the WEB Intra-saccular Therapy Study (WEB-IT)

Abstract

IntroductionThe Woven EndoBridge (WEB) represents a novel intrasaccular therapeutic option for the treatment of intracranial wide-necked bifurcation aneurysms (WNBAs).

The New Low-Profile WEB 17 System for Treatment of Intracranial Aneurysms: First Clinical Experiences

“…Our first results with the WEB 17 are in line with other studies using previous generations of the WEB or coils to treat intracranial aneurysms. [1][2][3][4][5][6][7][8][9][10][11][12][13][14] In a meta-analysis by Asnafi et al, 7 15 uncontrolled series were included, totaling 565 patients with 588 aneurysms treated with the WEB, of which 127 were ruptured. Initial complete and adequate occlusion rates were 27% and 59%, respectively.…”

“…Most of the published series comprised wideneck, unruptured aneurysms. [1][2][3][4][5][6][7][8][9][10][11][12][13][14] The first-generation WEBs required 0.027-to 0.033-inch microcatheters for delivery. In 2015, the WEB was redesigned for a 0.021-inch delivery microcatheter (WEB 21) in sizes ranging from 4 to 7 mm.…”

Physician training protocol within the WEB Intrasaccular Therapy (WEB-IT) study

“…Thirty-day safety results within the WEB-IT trial have been published and efficacy results will not be available until the end of the investigational device exemption trial 1. Safety results within WEB-IT were comparable to those seen in European WEB trials, even though physicians in Europe generally had a range of case experience with the WEB device before enrolling in EU WEB studies while the US WEB-IT investigators did not 2–5…”

“…The study enrolled 150 adults with WNBAs of the anterior and posterior intracranial circulations. All candidates were screened and approved by the study principal investigators on the basis of inclusion and exclusion criteria, which have been previously published 1. No roll-in cases were permitted within the trial.…”

Use of a next-generation multi-durometer long guide sheath for triaxial access in flow diversion: experience in 95 consecutive cases

“…This transition towards robust catheter access platforms is the result of advances in modern neuroendovascular devices requiring larger size delivery systems such as the Pipeline Embolization Device1 (PED; Medtronic Neurovascular, Irvine, California, USA), the Woven Endobridge Device2 (WEB; MicroVention Terumo, Tustin, California, USA) and the Surpass flow diverter3 (Stryker Neurovascular, Freemont, California, USA). Advances in ischemic stroke care with stentrievers and aspiration techniques have also driven neurointerventional procedures to the triaxial platform 4…”